Navigation Links
Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting

POWAY, Calif., Oct. 1 /PRNewswire/ -- Vet-Stem, Inc. announced that Dr. Robert Harman, DVM, MPVM, CEO of Vet-Stem, will present a talk entitled "Stem Cell Therapy: Mechanisms of Action" at the Annual Research Symposium of the American College of Veterinary Surgeons (ACVS) in Seattle, WA, October 21, 2010.  



Dr. Harman has presented at more than 40 veterinary and human stem cell conferences since the founding of Vet-Stem in 2002.  The ACVS is the largest veterinary surgical meeting in the world, with over 7,000 attendees from around the globe.  This seminar talk will provide continuing education for veterinarians on the most current research about how stem cells work to provide healing and improvement in quality of life of animals.

As the founder and scientific director of Vet-Stem, Dr. Harman has been at the forefront of development of the practical applications of stem cells in our animal populations and has consulted with a number of human stem cell companies to share these veterinary findings for the benefit of potential therapy for people.

Vet-Stem's clinical team has rapidly developed this market, training over 4,000 veterinarians in the United States alone and providing stem cells for treatment of over 7,000 horses and dogs.  Peer-reviewed publications in the journals Veterinary Therapeutics and the American Journal of Veterinary Research have demonstrated the effectiveness of these types of treatments in horses and dogs.  In addition, Dr. Harman has co-authored two publications on how these stem cells from fat tissue can help treat multiple sclerosis and autoimmune diseases in people.

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession.  This privately held company delivers stem cell and related services and products to veterinarians to treat diseases in dogs, cats and horses.  These technologies utilize the natural healing properties inherent in all animals to reduce pain and improve the quality of life of our pets.

In January of 2004, Vet-Stem introduced the first veterinary stem cell service in the United States.  Since that time there has been rapid adoption of this technology for treatment of tendon, ligament, and joint injuries by the veterinary community.  Published studies have confirmed that these stem cells can dramatically improve the healing of injuries and diseases that have had very few treatment options in the past.CONTACT INFORMATION:Michael DaleChief Operating Officer, VP Sales & MarketingVet-Stem, Inc.Ph: 858-748-2004 ext 102Fax:

SOURCE Vet-Stem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
2. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
3. Syndax Pharmaceuticals to Present at BIO Investor Forum
4. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
5. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
6. Oncothyreon to Present at JMP Securities Healthcare Conference
7. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
8. InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMDs TCT Satellite Symposium in Washington DC., Today.
9. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
10. Marshall Edwards CEO to Present at JMP Securities Healthcare Conference
11. Boehringer Ingelheim Presents New Phase III Data Evaluating Linagliptin in People with Type 2 Diabetes
Post Your Comments:
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... , November 25, 2015 ... Research Report is a professional and in-depth study ...      (Logo: ) , ... of the industry including definitions, classifications, applications and ... provided for the international markets including development trends, ...
(Date:11/24/2015)... HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... as the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, ... golf through his or her work with turfgrass. , Clarke, of Iselin, ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Paris , ... --> Paris , qui s,est tenu ... le leader de l,innovation biométrique, a inventé le premier ... empreintes sur la même surface de balayage. Jusqu,ici, deux ... pour les empreintes digitales. Désormais, un seul scanner est ...
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
Breaking Biology News(10 mins):